300642 透景生命
已收盘 12-29 15:00:00
资讯
新帖
简况
透景生命(300642.SZ)子公司取得医疗器械注册证
智通财经 · 12-19
透景生命(300642.SZ)子公司取得医疗器械注册证
透景生命(300642)披露控股子公司取得医疗器械注册证,12月15日股价下跌0.11%
证券之星 · 12-15
透景生命(300642)披露控股子公司取得医疗器械注册证,12月15日股价下跌0.11%
透景生命(300642.SZ)子公司取得一项医疗器械注册证
智通财经 · 12-15
透景生命(300642.SZ)子公司取得一项医疗器械注册证
透景生命最新公告:全资子公司江西透景申报的医疗器械注册申请获得受理
证券之星 · 12-01
透景生命最新公告:全资子公司江西透景申报的医疗器械注册申请获得受理
透景生命(300642)披露对外投资参股公司进展公告,11月18日股价下跌1.82%
证券之星 · 11-18
透景生命(300642)披露对外投资参股公司进展公告,11月18日股价下跌1.82%
透景生命最新公告:控股子公司申报医疗器械注册获得受理
证券之星 · 11-13
透景生命最新公告:控股子公司申报医疗器械注册获得受理
透景生命(300642)披露召开2025年第一次临时股东大会通知,11月12日股价上涨0.19%
证券之星 · 11-12
透景生命(300642)披露召开2025年第一次临时股东大会通知,11月12日股价上涨0.19%
透景生命最新公告:取得1项医疗器械注册证及8项注册申请受理
证券之星 · 10-31
透景生命最新公告:取得1项医疗器械注册证及8项注册申请受理
透景生命:武汉康录生物纳入合并报表范围
证券之星 · 10-24
透景生命:武汉康录生物纳入合并报表范围
透景生命最新公告:投资6800万元参股惠和生物其已完成CC312管线的早期临床研究
证券之星 · 10-23
透景生命最新公告:投资6800万元参股惠和生物其已完成CC312管线的早期临床研究
透景生命(300642)披露2025年三季度报告,10月22日股价下跌3.33%
证券之星 · 10-22
透景生命(300642)披露2025年三季度报告,10月22日股价下跌3.33%
透景生命(300642.SZ)发布前三季度业绩,归母净利润577.49万元,下降76.33%
智通财经 · 10-22
透景生命(300642.SZ)发布前三季度业绩,归母净利润577.49万元,下降76.33%
透景生命(300642)披露拟开展不超过2500万元应收账款无追索权保理业务,10月09日股价上涨0.59%
证券之星 · 10-09
透景生命(300642)披露拟开展不超过2500万元应收账款无追索权保理业务,10月09日股价上涨0.59%
透景生命:回购股份实施期限及进展
证券之星 · 09-10
透景生命:回购股份实施期限及进展
【机构调研记录】浦银安盛基金调研透景生命、东芯股份
证券之星 · 08-29
【机构调研记录】浦银安盛基金调研透景生命、东芯股份
股市必读:透景生命中报 - 第二季度单季净利润同比下降79.43%
证券之星 · 08-28
股市必读:透景生命中报 - 第二季度单季净利润同比下降79.43%
透景生命(300642)2025年中报简析:净利润同比下降58.41%,公司应收账款体量较大
证券之星 · 08-28
透景生命(300642)2025年中报简析:净利润同比下降58.41%,公司应收账款体量较大
透景生命最新公告:上半年净利润同比下降58.41%
证券之星 · 08-26
透景生命最新公告:上半年净利润同比下降58.41%
透景生命收盘上涨8.87%,滚动市盈率128.83倍,总市值50.88亿元
金融界 · 08-26
透景生命收盘上涨8.87%,滚动市盈率128.83倍,总市值50.88亿元
透景生命收盘上涨20.01%,滚动市盈率95.04倍,总市值37.53亿元
金融界 · 08-19
透景生命收盘上涨20.01%,滚动市盈率95.04倍,总市值37.53亿元
加载更多
公司概况
公司名称:
上海透景生命科技股份有限公司
所属行业:
医药制造业
上市日期:
2017-04-21
主营业务:
上海透景生命科技股份有限公司的主营业务是自主品牌的体外诊断产品的研发、生产和销售。公司的主要产品是体外诊断试剂、体外诊断仪器、服务收入。公司积极参与各类健康主题公益活动,比如全国三八妇女节公益活动、全国子宫颈癌和乳腺癌防治咨询公益活动等,践行社会担当,并连续多年荣获中国癌症基金会颁发的“社会公益奖”等多项奖项,积极履行社会责任。
发行价格:
36.10
{"stockData":{"symbol":"300642","market":"SZ","secType":"STK","nameCN":"透景生命","latestPrice":18.61,"timestamp":1766991780000,"preClose":18.77,"halted":0,"volume":2385500,"delay":0,"changeRate":-0.0085,"floatShares":138000000,"shares":163000000,"eps":0.098,"marketStatus":"已收盘","change":-0.16,"latestTime":"12-29 15:00:00","open":18.61,"high":18.78,"low":18.53,"amount":44399500,"amplitude":0.0133,"askPrice":18.61,"askSize":183,"bidPrice":18.6,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.098,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767058200000},"marketStatusCode":5,"adr":0,"adjPreClose":18.77,"symbolType":"stock","openAndCloseTimeList":[[1766971800000,1766979000000],[1766984400000,1766991600000]],"highLimit":20.65,"lowLimit":16.89,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":162544041,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":189.897959,"roe":"0.38%","epsLYR":0.213,"committee":-0.90293,"marketValue":3025000000,"turnoverRate":0.0173,"status":1,"floatMarketCap":2563000000},"requestUrl":"/m/hq/s/300642","defaultTab":"news","newsList":[{"id":"2592163072","title":"透景生命(300642.SZ)子公司取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163072","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592163072?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:45","pubTimestamp":1766141114,"startTime":"0","endTime":"0","summary":"智通财经APP讯,透景生命(300642.SZ)公告,公司全资子公司上海透景诊断科技有限公司近日取得上海市药品监督管理局颁发的5项医疗器械注册证,产品包括:抗双链DNA抗体IgG测定试剂盒(流式荧光发光法)、抗补体1q抗体IgG测定试剂盒(流式荧光发光法)、抗M2-3E抗体IgG测定试剂盒(流式荧光发光法)、抗磷脂综合征IgA抗体测定试剂盒(流式荧光发光法)、抗核小体抗体IgG测定试剂盒(流式荧光发光法)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1583","159883","BK1222","BK1574","BK0042","BK1100","300642","09997","BK0046","09996"],"gpt_icon":0},{"id":"2591642362","title":"透景生命(300642)披露控股子公司取得医疗器械注册证,12月15日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642362?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:18","pubTimestamp":1765808295,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘,透景生命报收于18.4元,较前一交易日下跌0.11%,最新总市值为29.91亿元。该股当日开盘18.31元,最高18.73元,最低18.23元,成交额达5063.15万元,换手率为1.99%。公司近日发布公告称,其控股子公司武汉康录生物技术股份有限公司取得国家药品监督管理局颁发的1项医疗器械注册证,产品名称为产前染色体数目检测试剂盒,注册证编号国械注准20253402555,有效期至2030年12月11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500035499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","BK1222","BK1583","BK0046","09996","BK0042","BK1100","159883","300642","BK1574","BK0239"],"gpt_icon":0},{"id":"2591612958","title":"透景生命(300642.SZ)子公司取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612958","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612958?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:45","pubTimestamp":1765791945,"startTime":"0","endTime":"0","summary":"智通财经APP讯,透景生命(300642.SZ)公告,公司控股子公司武汉康录生物技术股份有限公司近日取得国家药品监督管理局颁发的1项医疗器械注册证,产品名为:产前染色体数目检测试剂盒(荧光原位杂交法)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0046","BK0239","BK1100","159883","09997","09996","BK1222","BK0042","BK1583","300642"],"gpt_icon":0},{"id":"2588472610","title":"透景生命最新公告:全资子公司江西透景申报的医疗器械注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588472610","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588472610?lang=zh_cn&edition=full","pubTime":"2025-12-01 18:20","pubTimestamp":1764584401,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)公告称,全资子公司江西透景申报的4项医疗器械注册申请近日获得江西省药品监督管理局受理,包括2项全自动流式荧光发光免疫分析仪和2项全自动化学发光免疫分析仪。这些产品均为第二类体外诊断仪器,不同型号的受理有利于丰富公司及全资子公司在流式荧光及化学发光产品线的仪器配套,提高市场竞争力。但注册申请受理对公司及江西透景近期业绩不会产生影响,能否顺利取得医疗器械注册证书有待于江西省药品监督管理局的最终审评结论。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100025044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","09996","BK0042","BK1574","BK0046","BK0239","159883","BK1222","300642","BK1583","BK1100"],"gpt_icon":0},{"id":"2584953144","title":"透景生命(300642)披露对外投资参股公司进展公告,11月18日股价下跌1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584953144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584953144?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:13","pubTimestamp":1763475204,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘,透景生命报收于20.52元,较前一交易日下跌1.82%,最新总市值为33.36亿元。该股当日开盘20.93元,最高21.02元,最低20.35元,成交额达1.27亿元,换手率为4.49%。公司近日发布公告称,上海透景生命科技股份有限公司以自有资金6,800万元认购惠和生物技术(上海)有限公司新增注册资本17.5992万元,持股比例达9.2141%。截至目前,惠和生物已完成工商变更登记,透景生命已全额实缴投资款并取得出资证明书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0046","300642"],"gpt_icon":0},{"id":"2583591203","title":"透景生命最新公告:控股子公司申报医疗器械注册获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2583591203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583591203?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:09","pubTimestamp":1763046585,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)公告称,公司控股子公司武汉康录生物技术股份有限公司申报的境内体外诊断试剂注册申请近日获得国家药品监督管理局受理。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","BK0239","BK0046","300642","BK1583","BK1100","BK1574","BK1222","159883","09996","BK0042"],"gpt_icon":0},{"id":"2582321909","title":"透景生命(300642)披露召开2025年第一次临时股东大会通知,11月12日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582321909","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582321909?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:32","pubTimestamp":1762939939,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘,透景生命报收于21.1元,较前一交易日上涨0.19%,最新总市值为34.3亿元。该股当日开盘21.1元,最高21.62元,最低20.9元,成交额达1.68亿元,换手率为5.74%。公司近日发布公告称,将于2025年11月27日召开2025年第一次临时股东大会,会议由董事会召集,现场会议时间为当日14:00,网络投票时间为9:15至15:00。股权登记日为2025年11月20日。公司将提供网络投票平台,中小投资者表决将单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200028524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","300642","BK0046"],"gpt_icon":0},{"id":"2579468571","title":"透景生命最新公告:取得1项医疗器械注册证及8项注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2579468571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579468571?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:51","pubTimestamp":1761907862,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)公告称,公司近日收到上海市药品监督管理局颁发的1项医疗器械注册证,同时公司申报的8项医疗器械注册申请取得国家药品监督管理局的受理。新获注册证的试剂盒用于定量检测肺癌患者血清中相关肿瘤标志物浓度,而受理的8项产品主要涉及乙型肝炎病毒感染和呼吸道感染的检测。这些进展将丰富公司产品线,增强综合竞争力,但对近期业绩影响有限,未来销售情况取决于市场推广效果。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100041101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","159883","09996","BK1583","BK1100","300642","09997","BK1222","BK0046","BK0239","BK1574"],"gpt_icon":0},{"id":"2577155971","title":"透景生命:武汉康录生物纳入合并报表范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2577155971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577155971?lang=zh_cn&edition=full","pubTime":"2025-10-24 09:06","pubTimestamp":1761267984,"startTime":"0","endTime":"0","summary":"证券之星消息,透景生命(300642)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问:请问新合并的子公司在25年3季报中,扣非净利贡献多少?新合并公司今年业绩承诺已经完成多少?能否顺利完成?透景生命回复:感谢您的关注。武汉康录生物技术股份有限公司自2025年8月31日起纳入公司的合并报表范围,计入公司2025年三季度的业绩仅9月单月数据,其目前业绩情况与承诺净利润相匹配。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300642","BK0239","BK0042"],"gpt_icon":0},{"id":"2577372999","title":"透景生命最新公告:投资6800万元参股惠和生物其已完成CC312管线的早期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2577372999","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577372999?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:39","pubTimestamp":1761212384,"startTime":"0","endTime":"0","summary":"透景生命公告称,公司以自有资金6800万元认购惠和生物新增注册资本17.5992万元,增资完成后,公司将持有惠和生物9.2141%的股权。惠和生物主要管线CC312处于I期临床阶段,存在临床效果不达预期的风险。标的公司聚焦肿瘤和自免疾病创新治疗领域,其核心CC312管线针对的SLE等多种自身免疫疾病存在明确的临床未被满足需求,且已展现出良好的研发潜力。标的公司已完成CC312管线的早期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300027610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","300642","BK0239"],"gpt_icon":0},{"id":"2577428393","title":"透景生命(300642)披露2025年三季度报告,10月22日股价下跌3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577428393","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577428393?lang=zh_cn&edition=full","pubTime":"2025-10-22 22:12","pubTimestamp":1761142343,"startTime":"0","endTime":"0","summary":"截至2025年10月22日收盘,透景生命报收于25.86元,较前一交易日下跌3.33%,最新总市值为42.04亿元。近日,透景生命发布2025年第三季度报告。归属于上市公司股东的净利润方面,本报告期为3,015,658.87元,比上年同期减少83.02%;年初至报告期末为5,774,947.62元,比上年同期减少76.33%。经营活动产生的现金流量净额年初至报告期末为103,104,566.22元,比上年同期减少7.30%。前10名股东中,姚见儿持股20.15%,持股数量32,753,700股,为第一大股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200037493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0042","300642"],"gpt_icon":0},{"id":"2577362585","title":"透景生命(300642.SZ)发布前三季度业绩,归母净利润577.49万元,下降76.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577362585","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577362585?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:44","pubTimestamp":1761137089,"startTime":"0","endTime":"0","summary":"智通财经APP讯,透景生命(300642.SZ)发布2025年三季度报告,该公司前三季度营业收入为2.58亿元,同比减少19.73%。归属于上市公司股东的净利润为577.49万元,同比减少76.33%。归属于上市公司股东的扣除非经常性损益的净利润为137.32万元,同比减少90.45%。基本每股收益为0.0356元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"透景生命(300642.SZ)发布前三季度业绩,归母净利润577.49万元,下降76.33%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300642"],"gpt_icon":0},{"id":"2574169897","title":"透景生命(300642)披露拟开展不超过2500万元应收账款无追索权保理业务,10月09日股价上涨0.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574169897","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574169897?lang=zh_cn&edition=full","pubTime":"2025-10-09 22:49","pubTimestamp":1760021354,"startTime":"0","endTime":"0","summary":"截至2025年10月9日收盘,透景生命报收于23.72元,较前一交易日上涨0.59%,最新总市值为38.56亿元。公司于近日发布公告称,上海透景生命科技股份有限公司于2025年9月30日召开第四届董事会第十三次会议,审议通过《关于公司开展应收账款无追索权保理业务的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900034786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642","BK0046","BK0239","BK0042"],"gpt_icon":0},{"id":"2566084609","title":"透景生命:回购股份实施期限及进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2566084609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566084609?lang=zh_cn&edition=full","pubTime":"2025-09-10 20:51","pubTimestamp":1757508671,"startTime":"0","endTime":"0","summary":"公司本次以集中竞价交易方式回购股份方案的实施期限为公司董事会审议通过本次回购股份方案之日起12个月内,即2025年4月8日至2026年4月7日。截至2025年8月31日,公司通过股票回购专用账户以集中竞价交易方式累计回购股份287,900股,占公司当前总股本的0.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000035835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300642","BK0046","BK0239"],"gpt_icon":0},{"id":"2563098106","title":"【机构调研记录】浦银安盛基金调研透景生命、东芯股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2563098106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563098106?lang=zh_cn&edition=full","pubTime":"2025-08-29 08:03","pubTimestamp":1756425813,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月28日披露的机构调研信息,浦银安盛基金近期对2家上市公司进行了调研,相关名单如下:1)透景生命 调研纪要:公司控股子公司河北透景主要聚焦于侵袭性真菌病检测领域,已完成更名、整合和并表工作,助力真菌微生物检测产品研发、注册报批、临床推广。2)东芯股份 调研纪要:东芯股份副总经理、董事会秘书蒋雨舟女士介绍了公司2025年经营情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900008542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","688110","BK0046","BK0239","BK0214","300642"],"gpt_icon":0},{"id":"2562267776","title":"股市必读:透景生命中报 - 第二季度单季净利润同比下降79.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562267776","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562267776?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:44","pubTimestamp":1756334655,"startTime":"0","endTime":"0","summary":"来自业绩披露要点:2025年第二季度归母净利润同比下滑79.43%,扣非净利润仅34.93万元,同比下降96.0%。截至本公告披露日,公司累计回购股份0股,支付总金额为0元。本次调整回购股份价格上限符合相关规定,有利于保障回购股份事项顺利实施,不存在对公司债务履行能力及持续经营能力产生影响的情形,不会影响公司上市地位,亦不会导致公司控制权发生变化。本次调整回购股份价格上限事项无需提交公司股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800007520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642"],"gpt_icon":0},{"id":"2562776688","title":"透景生命(300642)2025年中报简析:净利润同比下降58.41%,公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2562776688","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562776688?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:29","pubTimestamp":1756333796,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期透景生命发布2025年中报。截至本报告期末,公司营业总收入1.59亿元,同比下降26.25%,归母净利润275.93万元,同比下降58.41%。按单季度数据看,第二季度营业总收入8416.71万元,同比下降31.35%,第二季度归母净利润228.76万元,同比下降79.43%。本报告期透景生命公司应收账款体量较大,当期应收账款占最新年报归母净利润比达558.13%。去年的净利率为6.5%,算上全部成本后,公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800006527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642"],"gpt_icon":0},{"id":"2562773385","title":"透景生命最新公告:上半年净利润同比下降58.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562773385","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562773385?lang=zh_cn&edition=full","pubTime":"2025-08-26 19:31","pubTimestamp":1756207878,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)发布2025年半年度报告,公司实现营业收入1.59亿元,同比下降26.25%;归属于上市公司股东的净利润为275.93万元,同比下降58.41%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600041901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642"],"gpt_icon":0},{"id":"2562784628","title":"透景生命收盘上涨8.87%,滚动市盈率128.83倍,总市值50.88亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562784628","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562784628?lang=zh_cn&edition=full","pubTime":"2025-08-26 17:41","pubTimestamp":1756201319,"startTime":"0","endTime":"0","summary":"8月26日,透景生命今日收盘31.3元,上涨8.87%,滚动市盈率PE达到128.83倍,创871天以来新低,总市值50.88亿元。从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均54.91倍,行业中值40.90倍,透景生命排名第107位。资金流向方面,8月26日,透景生命主力资金净流入5855.66万元,近5日总体呈流入状态,5日共流入22637.59万元。最新一期业绩显示,2025年一季报,公司实现营业收入7489.31万元,同比-19.53%;净利润47.17万元,同比110.51%,销售毛利率63.66%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26174152704012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0046","300642","BK0239","BK0042"],"gpt_icon":0},{"id":"2560162287","title":"透景生命收盘上涨20.01%,滚动市盈率95.04倍,总市值37.53亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560162287","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560162287?lang=zh_cn&edition=full","pubTime":"2025-08-19 17:40","pubTimestamp":1755596452,"startTime":"0","endTime":"0","summary":"8月19日,透景生命今日收盘23.09元,上涨20.01%,滚动市盈率PE达到95.04倍,创566天以来新低,总市值37.53亿元。从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均59.49倍,行业中值40.19倍,透景生命排名第103位。资金流向方面,8月19日,透景生命主力资金净流入9881.58万元,近5日总体呈流入状态,5日共流入10257.98万元。最新一期业绩显示,2025年一季报,公司实现营业收入7489.31万元,同比-19.53%;净利润47.17万元,同比110.51%,销售毛利率63.66%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/19174052537559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0046","300642","BK0042"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767031076225,"stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.2108},{"period":"6month","weight":0.2626},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.332}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1478},{"period":"1year","weight":0.1662},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海透景生命科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18785人(较上一季度增加17.52%)","perCapita":"7330股","listingDate":"2017-04-21","address":"上海市浦东新区汇庆路412号","registeredCapital":"16254万元","survey":" 上海透景生命科技股份有限公司的主营业务是自主品牌的体外诊断产品的研发、生产和销售。公司的主要产品是体外诊断试剂、体外诊断仪器、服务收入。公司积极参与各类健康主题公益活动,比如全国三八妇女节公益活动、全国子宫颈癌和乳腺癌防治咨询公益活动等,践行社会担当,并连续多年荣获中国癌症基金会颁发的“社会公益奖”等多项奖项,积极履行社会责任。","listedPrice":36.1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"透景生命(300642)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供透景生命(300642)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"透景生命,300642,透景生命股票,透景生命股票老虎,透景生命股票老虎国际,透景生命行情,透景生命股票行情,透景生命股价,透景生命股市,透景生命股票价格,透景生命股票交易,透景生命股票购买,透景生命股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"透景生命(300642)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供透景生命(300642)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}